Combinations of anti-cancer drugs can overcome resistance and provide new treatments,.
The number of possible drug combinations vastly exceeds what could be tested clinically …

To the Editor: The Cancer Genome Atlas (TCGA, https://tcgadata. nci. nih. gov/tcga/) has
been generating multimodal genomics, epigenomics and proteomics data for thousands of …

Metastasis is the principal event leading to death in individuals with cancer, yet its molecular
basis is poorly understood 1. To explore the molecular differences between human primary …

INTRODUCTION Cancer is a leading cause of death worldwide, and there is great need to
define the molecular mechanisms driving the development and progression of individual …

Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …

Pancreatic cancer is an aggressive malignancy with a five-year mortality of 97–98%, usually
due to widespread metastatic disease. Previous studies indicate that this disease has a …

Early successes in identifying and targeting individual oncogenic drivers, together with the
increasing feasibility of sequencing tumor genomes, have brought forth the promise of …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

Single-cell genomics enables dissection of tumor heterogeneity and molecular
underpinnings of drug response at an unprecedented resolution,,,,,,,,,–. However, broad …